MX2023003007A - Vacuna de sinucleina alfa para el tratamiento de sinucleinopatias. - Google Patents
Vacuna de sinucleina alfa para el tratamiento de sinucleinopatias.Info
- Publication number
- MX2023003007A MX2023003007A MX2023003007A MX2023003007A MX2023003007A MX 2023003007 A MX2023003007 A MX 2023003007A MX 2023003007 A MX2023003007 A MX 2023003007A MX 2023003007 A MX2023003007 A MX 2023003007A MX 2023003007 A MX2023003007 A MX 2023003007A
- Authority
- MX
- Mexico
- Prior art keywords
- alpha
- synuclein
- synucleinopathies
- peptide
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063079819P | 2020-09-17 | 2020-09-17 | |
| PCT/US2021/045055 WO2022060487A1 (en) | 2020-09-17 | 2021-08-06 | Alpha-synuclein vaccine for the treatment of synucleinopathies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023003007A true MX2023003007A (es) | 2023-04-10 |
Family
ID=80777122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023003007A MX2023003007A (es) | 2020-09-17 | 2021-08-06 | Vacuna de sinucleina alfa para el tratamiento de sinucleinopatias. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230355756A1 (https=) |
| EP (1) | EP4213867A4 (https=) |
| JP (1) | JP2023541671A (https=) |
| KR (1) | KR20230087487A (https=) |
| CN (1) | CN116783211A (https=) |
| AR (1) | AR123189A1 (https=) |
| AU (1) | AU2021344230A1 (https=) |
| CA (1) | CA3192429A1 (https=) |
| IL (1) | IL301224A (https=) |
| MX (1) | MX2023003007A (https=) |
| TW (1) | TW202227465A (https=) |
| WO (1) | WO2022060487A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025507875A (ja) | 2022-02-28 | 2025-03-21 | トライデム バイオサイエンス ゲーエムベーハー ウント コンパニー カーゲー | 少なくともβ－グルカン若しくはマンナンからなるか、又はこれを含む結合体 |
| WO2023161528A1 (en) | 2022-02-28 | 2023-08-31 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN |
| KR20260021636A (ko) | 2023-06-15 | 2026-02-13 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 프라이머 조성물, 접착 시스템, 및 관련 공정 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2657953A1 (en) * | 2005-07-19 | 2007-01-25 | University Of Rochester | Alpha-synuclein antibodies and methods related thereto |
| PL2118300T3 (pl) * | 2007-02-23 | 2015-11-30 | Prothena Biosciences Ltd | Zapobieganie i leczenie synukleinopatii i amyloidozy |
| US8147833B2 (en) * | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| HUE025225T2 (en) * | 2007-02-23 | 2016-02-29 | Prothena Biosciences Ltd | Prevention and treatment of synucleinopathic and amyloidogenic diseases |
| AU2008293504B2 (en) * | 2007-08-27 | 2012-04-12 | Longhorn Vaccines & Diagnostics, Llc | Immunogenic compositions and methods |
| CA2885924C (en) * | 2012-08-21 | 2022-12-13 | Institute For Molecular Medicine, Inc. | Compositions and methods related to diseases associated with deposits of amyloid, tau, and alpha-synuclein |
| AU2013344571A1 (en) * | 2012-11-16 | 2015-06-04 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Gonorrheal MtrE peptides and vaccines |
| CN110506057B (zh) * | 2017-02-17 | 2023-09-29 | 百时美施贵宝公司 | Alpha突触核蛋白抗体及其应用 |
| BR112019026707A2 (pt) * | 2017-06-16 | 2020-06-30 | United Neuroscience | imunógenos de peptídeo da extremidade c-terminal da proteína alfa-sinucleína e formulações dos mesmos para o tratamento de sinucleinopatias |
| WO2019070480A1 (en) * | 2017-10-02 | 2019-04-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | ASSAY FOR DETECTION OF ALPHA-SYNUCLEIN SELF-ACTIVATION ACTIVITY ASSOCIATED WITH SYNUCLEINOPATHIES |
| KR102710762B1 (ko) * | 2017-10-25 | 2024-09-25 | 얀센 파마슈티칼즈, 인코포레이티드 | 인산화 타우 펩티드의 조성물 및 이의 용도 |
| CN112368386A (zh) * | 2018-05-23 | 2021-02-12 | 磨石肿瘤生物技术公司 | 共有抗原 |
-
2021
- 2021-08-06 JP JP2023517699A patent/JP2023541671A/ja active Pending
- 2021-08-06 KR KR1020237012532A patent/KR20230087487A/ko active Pending
- 2021-08-06 WO PCT/US2021/045055 patent/WO2022060487A1/en not_active Ceased
- 2021-08-06 MX MX2023003007A patent/MX2023003007A/es unknown
- 2021-08-06 EP EP21869943.7A patent/EP4213867A4/en active Pending
- 2021-08-06 IL IL301224A patent/IL301224A/en unknown
- 2021-08-06 CA CA3192429A patent/CA3192429A1/en active Pending
- 2021-08-06 US US18/245,533 patent/US20230355756A1/en active Pending
- 2021-08-06 CN CN202180064031.1A patent/CN116783211A/zh active Pending
- 2021-08-06 AU AU2021344230A patent/AU2021344230A1/en active Pending
- 2021-08-09 AR ARP210102220A patent/AR123189A1/es unknown
- 2021-08-09 TW TW110129346A patent/TW202227465A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230087487A (ko) | 2023-06-16 |
| CN116783211A (zh) | 2023-09-19 |
| TW202227465A (zh) | 2022-07-16 |
| IL301224A (en) | 2023-05-01 |
| EP4213867A4 (en) | 2025-04-09 |
| US20230355756A1 (en) | 2023-11-09 |
| AU2021344230A1 (en) | 2023-04-13 |
| CA3192429A1 (en) | 2022-03-24 |
| EP4213867A1 (en) | 2023-07-26 |
| WO2022060487A1 (en) | 2022-03-24 |
| AR123189A1 (es) | 2022-11-09 |
| JP2023541671A (ja) | 2023-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022553234A1 (en) | Multi-epitope vaccine for the treatment of alzheimer`s disease | |
| MX2023003009A (es) | Vacuna de beta-amiloide para el tratamiento de la enfermedad de alzheimer. | |
| MX2023001503A (es) | Vacuna de multiples epitopos para tratamiento de la enfermedad de alzheimer. | |
| MX2023003007A (es) | Vacuna de sinucleina alfa para el tratamiento de sinucleinopatias. | |
| MX2023003008A (es) | Vacuna de multiples epitopos para el tratamiento de la enfermedad de alzheimer. | |
| CR20210563A (es) | Compuestos y métodos para el tratamiento de covid-19 | |
| MX2022016276A (es) | Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson. | |
| MX2023001501A (es) | Vacuna tau para tratamiento de enfermedad de alzheimer. | |
| EP4119577A3 (en) | Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders | |
| TW200512195A (en) | Benzamide 2-hydroxy-3-diaminoalkanes | |
| MXPA04006575A (es) | Amino carboxamidas sustituidas para el tratamiento de la enfermedad de alzheimer. | |
| MXPA04002785A (es) | Aminas sustituidas para tratamiento de enfermedad de alzheimer. | |
| WO2021252895A3 (en) | Compositions and methods for the treatment and prevention of neurological disorders | |
| RU2017121836A (ru) | Нейродегенеративные расстройства | |
| MX2024010655A (es) | Uso de profarmacos de riluzol para tratar enfermedad de alzheimer. | |
| ZA202002103B (en) | Compounds as mpges-1 inhibitors | |
| MX2017002476A (es) | Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matriz extracelular. | |
| MX2023014669A (es) | Compuestos utiles en el tratamiento o prevencion de un trastorno mediado por prmt5. | |
| MX2024002875A (es) | Tratamiento de trastornos neurologicos. | |
| TW200510351A (en) | Oxazole compounds for the treatment of neurodegenerative disorders | |
| MX2023006704A (es) | Composiciones dsg2 y metodos para el tratamiento de covid-19. | |
| Rodda et al. | Quality of life outcomes: ASCENDE-RT a multicenter randomized trial of radiation therapy for prostate cancer | |
| MX2023010831A (es) | Composiciones y metodos para tratar enfermedades neurologicas. | |
| MX2024003930A (es) | Moduladores de trpml, sus composiciones y metodos de uso. | |
| MX2019003720A (es) | Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. |